Excelsior Correspondent
JAMMU, June 5: Syncom Formulations (India) Ltd , a specialty pharmaceutical formulation company reported its excellent performance for 4th quarter and year ended 31st March 25.
The company has reported a 139% rise in net profit for the fourth quarter of FY25, with profit after tax reaching Rs 1,769 lakh, up from Rs 740 lakh a year earlier.
Quarterly revenue doubled to Rs 14,888 lakh, while EBITDA rose 97% to Rs 2,469 lakh.
For the full fiscal year, revenue climbed 76% to Rs 46,501 lakh and annual net profit nearly doubled to Rs 4,943 lakh.
The company attributed the strong performance to growing demand, operational efficiency, and expansion in both domestic and global markets.
Established in 1988, Syncom Formulations (India) Limited has grown into a leading name in the Indian pharmaceutical sector.
The company has consistently posted profits since inception and is renowned for delivering high-quality pharmaceutical formulations across diverse therapeutic segments.
“We are proud of our performance this year, which reflects the success of our strategic initiatives, operational efficiency, and strong demand in both domestic and international markets. We remain committed to expanding our global presence and delivering sustained value to all stakeholders,” said the company in a handout issued.
With operations in 25 countries and over 400 registered products, Syncom plans to deepen its presence in India through a strong marketing network and focused healthcare divisions.
Follow our WhatsApp channel
